Literature DB >> 21365856

[Counterfeit phosphodiesterase type 5 inhibitors--growing safety risks for public health].

Zbigniew Fijałek1, Katarzyna Sarna, Agata Błazewicz, Jan Marin.   

Abstract

Counterfeit drugs, medical devises and dietary supplements are inherently dangerous and a growing problem. In Europe the growth of the counterfeit medication market is attributable in part to registration of phosphodiesterase type 5 inhibitors (PDE-5) used for the erectile dysfunction. "Viagra, Levitra and Cialis belong to this group. It has been estimated that up to 2.5 million men in Europe are exposed to an illicit sildenafil, suggesting that there may be as many illegal as legal users of sildenafil. In Europe a strong trend is observed towards increasingly professional counterfeits and imitations of Viagra, Cialis and Levitra, with regard to the appearance of tablets, capsules and packaging. The professional presentation will deceive potential consumers into assuming these products are legal, efficacious and safe. Globally, increased obstacles for counterfeiters are necessary to combat pharmaceutical counterfeiting, including fines and penalties. The worldwide nature of the counterfeit problem requires proper coordination between countries to ensure an adequate enforcement. We described the usefulness of the time-of-flight mass spectrometry with the electrospray ionization (LC-ESI-MS-TOF) and the X-ray powder diffraction method (XRPD) for PDE-5 counterfeit screening from the Polish illegal market.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21365856

Source DB:  PubMed          Journal:  Rocz Panstw Zakl Hig        ISSN: 0035-7715


  1 in total

1.  The European Falsified Medicines Directive in Poland: background, implementation and potential recommendations for pharmacists.

Authors:  Piotr Merks; Damian Swieczkowski; Michal Byliniak; Mariola Drozd; Katarzyna Krupa; Milosz Jaguszewski; David A Brindley; Bernard D Naughton
Journal:  Eur J Hosp Pharm       Date:  2016-07-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.